Niagen Bioscience, Inc.

The balance sheet looks solid with $66.4M in cash comfortably exceeding the $2.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$1.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at 27.1%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 7.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $72.0M (2022) to $129.4M (2025), reflecting a 80% increase over the period.

With a beta above 1.5, NAGE tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, NAGE has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Niagen Bioscience, Inc. and its sector.